Compare Ascendis Pharma A/S (ASND) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Snap On Incorporated — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Snap On Incorporated trades at $401.94 (market cap $20.82B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays a 2.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SNA | |
|---|---|---|
Market Cap | $17.74B | $20.82B |
Sector | Health | Technology |
52-Week High | $277.18 | $413.62 |
52-Week Low | $163.32 | $313.01 |
Enterprise Value | $18.11B | $20.34B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Snap-on Incorporated (SNA) trades at $401.94, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong profitability with a 19.6% net income margin and a 17.83% ROE for 2025. Recent strategic acquisitions, including Diesel Laptops for $100 million, aim to expand its heavy-duty diagnostics capabilities, while a $500 million share repurchase authorization and consistent dividends underscore shareholder returns.
The outlook is positive, supported by operational agility and steady cash flow growth, with net cash flow rising to $318 million projected for 2026. Key risks include muted revenue growth and margin pressures, as seen in the Q1 2026 earnings miss. Investor sentiment is cautiously optimistic, with 65% of analysts rating the stock a buy, but competitive and macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
